Proposal for a Non-randomized, Patient Sponsored, Multi-center Study Studying the Impact and Safety of the Utilization of Culture Expanded Autologous, Adipose-derived Mesenchymal Stem Cells Deployed Via Intravenous Injection for the Treatment of Multiple Sclerosis

Trial Profile

Proposal for a Non-randomized, Patient Sponsored, Multi-center Study Studying the Impact and Safety of the Utilization of Culture Expanded Autologous, Adipose-derived Mesenchymal Stem Cells Deployed Via Intravenous Injection for the Treatment of Multiple Sclerosis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Adipose-derived autologous stem cell therapy American CryoStem Corporation (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors American CryoStem Corporation
  • Most Recent Events

    • 13 Feb 2017 Planned End Date changed from 1 Nov 2017 to 1 Jan 2019.
    • 13 Feb 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Jan 2018.
    • 06 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top